ADAMA Ltd.’s Post

View organization page for ADAMA Ltd., graphic

266,329 followers

The EU has officially approved the renewal of Folpet and Captan - two crucial active ingredients (AIs) in multi-site fungicides, essential for European growers. With this approval, our products based on these vital AIs will continue to be available to farmers across Europe. 🌿 Both Folpet and Captan underwent rigorous re-evaluation, and we're proud to have played a key role in this renewal process, by providing extensive data that demonstrated their ongoing safety. Without this approval, farmers would have faced significant challenges, with no viable alternatives available in the market. 👏 This decision is a major win for the agricultural community, ensuring that farmers have the tools they need to thrive. It also reaffirms ADAMA's commitment to providing safe and effective solutions to protect crops against fungal diseases. Read more about this important milestone and how we're dedicated to supporting farmers with the tools they need to succeed. ➡️

ADAMA Continues Support for EU Growers Following 15 Year Renewal of Folpet and Captan

ADAMA Continues Support for EU Growers Following 15 Year Renewal of Folpet and Captan

adama.com

Pullaiah Narahari

Portfolio Specialist - Multifunction Expert E2E (Strategy, Dev, Reg, IP) : Passion to crops, segments, geographies , Exposing to diversified culture ,Team Building ,GTM ,Value Creation with Business Orientation.

2mo

Great News.Enablea continuity in supporting EU fatlrmaers and as well as positive mind set to other regulators outside Europe on Folpet.

Yair Jackson

Experienced Chemicals Development and Marketing manager, Strategy & Market analysis

2mo

Good News!

Like
Reply
Carlos Pantoja Bassi

Supply Chain Manager LATAM, MBA

2mo

¡Buenas noticias!

Fabio di Biase

Trial Coordinator and GLP Study Director presso Eurofins Agroscience Services

2mo

Well done💪

Like
Reply
Christine Rushby

Business Development Manager bei IBACON GmbH

2mo

Good news indeed!!

See more comments

To view or add a comment, sign in

Explore topics